Home » GAO: FDA Lacks “Clear and Effective Processes” for Postmarket Safety

GAO: FDA Lacks “Clear and Effective Processes” for Postmarket Safety

Overview:

FDA needs to better track postmarket drug safety issues, and improve its decisionmaking—these the key findings of a recent report from the government accountability office.

Author: GAO

Find more white papers on Quality Assurance Control

View all white papers »

More content on this topic:

  • Featured White Papers